ZNTL
Zentalis Pharmaceuticals, Inc.1.3800
-0.0200-1.43%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
99.71MP/E (TTM)
-Basic EPS (TTM)
-2.08Dividend Yield
0%Recent Filings
8-K
8-K
Zentalis buys back shares
Zentalis repurchased 7,500,000 shares from Matrix Capital at $1.33 each—below the $1.40 close on December 12—closing December 15, 2025, amid Matrix's fund wind-down. Board shrank to six after Karan Takhar's immediate resignation that day, with no disagreements noted. Cash runway holds into late 2027.
8-K
Q3 loss narrows, DENALI on track
Zentalis reported Q3 2025 net loss of $26.7M, down from $40.2M year-over-year, with R&D expenses dropping to $23.0M from $36.8M amid disciplined execution. DENALI Phase 2 trial in Cyclin E1-positive PROC stays on track for topline data by year-end 2026, potentially supporting accelerated approval pending FDA feedback. Cash of $280.7M funds operations into late 2027. TETON enrollment complete.
10-Q
Q3 FY2025 results
Zentalis narrowed Q3 FY2025 losses to $26.7M from $40.2M y/y, as R&D expenses dropped 38% to $23.0M (derived) from cuts in personnel and clinical costs post-January restructuring that trimmed headcount 40%. Operating loss improved to $33.7M from $51.4M y/y, with diluted EPS at -$0.37 versus -$0.56; YTD net loss shrank to $101.8M from $118.4M despite $7.8M restructuring charge, reconciling to 71.9M diluted shares. Cash burn eased to $27.0M (derived) for Q3, ending with $39.1M cash plus $239.2M marketable securities and no debt. R&D focused on azenosertib external costs at $12.6M. Clinical trials may fail to meet FDA standards.
8-K
CLO transition at Zentalis
Zentalis Pharmaceuticals announced on August 26, 2025, that Chief Legal Officer Andrea Paul will resign effective September 18 to join a major law firm, remaining as a non-executive employee until October 1 with a release agreement providing her 2025 bonus and continued equity vesting. The company swiftly appointed James B. Bucher, a veteran life sciences executive with over 30 years of experience in transactions and governance, to the role starting the same date. Bucher's expertise in mergers and capital raises bolsters Zentalis as it advances azenosertib into registration trials. Leadership transitions carry risks to continuity.
ARTL
Artelo Biosciences, Inc.
1.84+0.01
ATOS
Atossa Therapeutics, Inc.
0.72+0.01
ENTO
Entero Therapeutics Inc.
2.99+0.15
LSTA
Lisata Therapeutics, Inc.
2.05+0.01
NUVL
Nuvalent, Inc.
102.63-2.34
NVCT
Nuvectis Pharma, Inc.
7.69+0.04
OTLC
Oncotelic Therapeutics, Inc.
0.09+0.00
PTHS
Pelthos Therapeutics Inc.
21.83-0.42
ZBIO
Zenas BioPharma, Inc.
36.89+4.30
ZLAB
Zai Lab Limited
17.00-0.34